메뉴 건너뛰기




Volumn 103, Issue , 2018, Pages 244-251

Corrigendum to “Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials” (Journal of Psychiatric Research (2018) 103 (244–251), (S0022395618300979) (10.1016/j.jpsychires.2018.06.005));Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials

Author keywords

Antipsychotic; CRD42017077711; Lurasidone; Meta analysis; PROSPERO; Schizophrenia

Indexed keywords

LURASIDONE; PLACEBO; NEUROLEPTIC AGENT;

EID: 85048525540     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2018.08.019     Document Type: Erratum
Times cited : (21)

References (44)
  • 1
    • 0004171473 scopus 로고
    • Scale for the Assessment of Negative Symptoms (SANS)
    • University of Iowa Iowa City,IA
    • Andreasen, N.C., Scale for the Assessment of Negative Symptoms (SANS). 1983, University of Iowa, Iowa City,IA.
    • (1983)
    • Andreasen, N.C.1
  • 2
    • 0004171473 scopus 로고
    • Scale for the Assessment of Positive Symptoms (SAPS)
    • University of Iowa Iowa City,IA
    • Andreasen, N.C., Scale for the Assessment of Positive Symptoms (SAPS). 1984, University of Iowa, Iowa City,IA.
    • (1984)
    • Andreasen, N.C.1
  • 5
    • 78650664657 scopus 로고    scopus 로고
    • Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic
    • Citrome, L., Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin. Schizophrenia Relat. Psychoses 4 (2011), 251–257.
    • (2011) Clin. Schizophrenia Relat. Psychoses , vol.4 , pp. 251-257
    • Citrome, L.1
  • 6
    • 23944456070 scopus 로고    scopus 로고
    • Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement
    • Citrome, L., Volavka, J., Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. J. Clin. Psychiatr. 66 (2005), 1073–1074.
    • (2005) J. Clin. Psychiatr. , vol.66 , pp. 1073-1074
    • Citrome, L.1    Volavka, J.2
  • 7
    • 65349112410 scopus 로고    scopus 로고
    • Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials
    • Correll, C.U., Rummel-Kluge, C., Corves, C., Kane, J.M., Leucht, S., Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 35 (2009), 443–457.
    • (2009) Schizophr. Bull. , vol.35 , pp. 443-457
    • Correll, C.U.1    Rummel-Kluge, C.2    Corves, C.3    Kane, J.M.4    Leucht, S.5
  • 8
    • 85019175108 scopus 로고    scopus 로고
    • Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
    • Correll, C.U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatr. 16 (2017), 163–180.
    • (2017) World Psychiatr. , vol.16 , pp. 163-180
    • Correll, C.U.1    Solmi, M.2    Veronese, N.3    Bortolato, B.4    Rosson, S.5    Santonastaso, P.6
  • 9
    • 84865253275 scopus 로고    scopus 로고
    • Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis
    • De Hert, M., Yu, W., Detraux, J., Sweers, K., van Winkel, R., Correll, C.U., Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26 (2012), 733–759.
    • (2012) CNS Drugs , vol.26 , pp. 733-759
    • De Hert, M.1    Yu, W.2    Detraux, J.3    Sweers, K.4    van Winkel, R.5    Correll, C.U.6
  • 10
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Contr. Clin. Trials 7 (1986), 177–188.
    • (1986) Contr. Clin. Trials , vol.7 , pp. 177-188
    • DerSimonian, R.1    Laird, N.2
  • 11
    • 0033934949 scopus 로고    scopus 로고
    • Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
    • Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
    • (2000) Biometrics , vol.56 , pp. 455-463
    • Duval, S.1    Tweedie, R.2
  • 12
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
    • (1997) BMJ , vol.315 , pp. 629-634
    • Egger, M.1    Davey Smith, G.2    Schneider, M.3    Minder, C.4
  • 13
    • 85027887125 scopus 로고    scopus 로고
    • Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-Week, randomized placebo-controlled study
    • Goldman, R., Loebel, A., Cucchiaro, J., Deng, L., Findling, R.L., Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-Week, randomized placebo-controlled study. J. Child Adolesc. Psychopharmacol. 27 (2017), 516–525.
    • (2017) J. Child Adolesc. Psychopharmacol. , vol.27 , pp. 516-525
    • Goldman, R.1    Loebel, A.2    Cucchiaro, J.3    Deng, L.4    Findling, R.L.5
  • 14
    • 85041427492 scopus 로고    scopus 로고
    • Effect of adjunctive ranitidine for antipsychotic-induced weight gain: a systematic review of randomized placebo-controlled trials
    • Gu, X.J., Chen, R., Sun, C.H., Zheng, W., Yang, X.H., Wang, S.B., et al. Effect of adjunctive ranitidine for antipsychotic-induced weight gain: a systematic review of randomized placebo-controlled trials. J. Int. Med. Res. 46 (2018), 22–32.
    • (2018) J. Int. Med. Res. , vol.46 , pp. 22-32
    • Gu, X.J.1    Chen, R.2    Sun, C.H.3    Zheng, W.4    Yang, X.H.5    Wang, S.B.6
  • 16
    • 84887346660 scopus 로고    scopus 로고
    • Cochrane handbook for Systematic Reviews of Interventions
    • John Wiley & Sons,Ltd Chichester, UK
    • Higgins, J., Higgins, J., Cochrane handbook for Systematic Reviews of Interventions. 2008, John Wiley & Sons,Ltd, Chichester, UK.
    • (2008)
    • Higgins, J.1    Higgins, J.2
  • 17
    • 0037098199 scopus 로고    scopus 로고
    • Quantifying heterogeneity in a meta-analysis
    • Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med. 21 (2002), 1539–1558.
    • (2002) Stat. Med. , vol.21 , pp. 1539-1558
    • Higgins, J.P.1    Thompson, S.G.2
  • 18
    • 77953753014 scopus 로고    scopus 로고
    • Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity
    • Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Therapeut. 334 (2010), 171–181.
    • (2010) J. Pharmacol. Exp. Therapeut. , vol.334 , pp. 171-181
    • Ishibashi, T.1    Horisawa, T.2    Tokuda, K.3    Ishiyama, T.4    Ogasa, M.5    Tagashira, R.6
  • 20
    • 0023606101 scopus 로고
    • The positive and negative syndrome scale (PANSS) for schizophrenia
    • Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
    • (1987) Schizophr. Bull. , vol.13 , pp. 261-276
    • Kay, S.R.1    Fiszbein, A.2    Opler, L.A.3
  • 21
    • 85048533946 scopus 로고    scopus 로고
    • (lurasidone HCl) Tablets US Prescribing Information
    • Latuda, (lurasidone HCl) Tablets US Prescribing Information. 2012 http://www.latuda.com/LatudaPrescribingInformation.pdf.
    • (2012)
    • Latuda1
  • 22
    • 58049157203 scopus 로고    scopus 로고
    • Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    • Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373 (2009), 31–41.
    • (2009) Lancet , vol.373 , pp. 31-41
    • Leucht, S.1    Corves, C.2    Arbter, D.3    Engel, R.R.4    Li, C.5    Davis, J.M.6
  • 23
    • 60349086480 scopus 로고    scopus 로고
    • A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    • Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatr. 166 (2009), 152–163.
    • (2009) Am. J. Psychiatr. , vol.166 , pp. 152-163
    • Leucht, S.1    Komossa, K.2    Rummel-Kluge, C.3    Corves, C.4    Hunger, H.5    Schmid, F.6
  • 24
    • 84875255343 scopus 로고    scopus 로고
    • Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial
    • Loebel, A., Cucchiaro, J., Sarma, K., Xu, L., Hsu, C., Kalali, A.H., et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr. Res. 145 (2013), 101–109.
    • (2013) Schizophr. Res. , vol.145 , pp. 101-109
    • Loebel, A.1    Cucchiaro, J.2    Sarma, K.3    Xu, L.4    Hsu, C.5    Kalali, A.H.6
  • 25
    • 84921057771 scopus 로고    scopus 로고
    • Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies
    • Loebel, A., Cucchiaro, J., Silva, R., Mao, Y., Xu, J., Pikalov, A., et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. Eur. Psychiatr. 30 (2015), 26–31.
    • (2015) Eur. Psychiatr. , vol.30 , pp. 26-31
    • Loebel, A.1    Cucchiaro, J.2    Silva, R.3    Mao, Y.4    Xu, J.5    Pikalov, A.6
  • 26
    • 85007591469 scopus 로고    scopus 로고
    • Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study
    • Loebel, A., R S, R G, K W, J C, L C, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J. Clin. Psychiatr. 77 (2016), 1672–1680.
    • (2016) J. Clin. Psychiatr. , vol.77 , pp. 1672-1680
    • Loebel, A.1    R, S.2    R, G.3    K, W.4    J, C.5    L, C.6
  • 27
    • 80052477010 scopus 로고    scopus 로고
    • Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study
    • Meltzer, H.Y., J C, R S, M O, D P, J X, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatr. 168 (2011), 957–967.
    • (2011) Am. J. Psychiatr. , vol.168 , pp. 957-967
    • Meltzer, H.Y.1    J, C.2    R, S.3    M, O.4    D, P.5    J, X.6
  • 28
    • 69149107165 scopus 로고    scopus 로고
    • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • w64
    • Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (2009), 264–269 w64.
    • (2009) Ann. Intern. Med. , vol.151 , pp. 264-269
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 29
    • 67649222011 scopus 로고    scopus 로고
    • Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial
    • Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatr. 70 (2009), 829–836.
    • (2009) J. Clin. Psychiatr. , vol.70 , pp. 829-836
    • Nakamura, M.1    Ogasa, M.2    Guarino, J.3    Phillips, D.4    Severs, J.5    Cucchiaro, J.6
  • 30
    • 84995356823 scopus 로고    scopus 로고
    • Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
    • Nasrallah, H.A., Cucchiaro, J.B., Mao, Y., Pikalov, A.A., Loebel, A.D., Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 20 (2015), 140–147.
    • (2015) CNS Spectr. , vol.20 , pp. 140-147
    • Nasrallah, H.A.1    Cucchiaro, J.B.2    Mao, Y.3    Pikalov, A.A.4    Loebel, A.D.5
  • 31
    • 84875270413 scopus 로고    scopus 로고
    • Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study
    • Nasrallah, H.A., Silva, R., Phillips, D., Cucchiaro, J., Hsu, J., Xu, J., et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J. Psychiatr. Res. 47 (2013), 670–677.
    • (2013) J. Psychiatr. Res. , vol.47 , pp. 670-677
    • Nasrallah, H.A.1    Silva, R.2    Phillips, D.3    Cucchiaro, J.4    Hsu, J.5    Xu, J.6
  • 32
    • 84873710953 scopus 로고    scopus 로고
    • Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
    • Ogasa, M., Kimura, T., Nakamura, M., Guarino, J., Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology 225 (2013), 519–530.
    • (2013) Psychopharmacology , vol.225 , pp. 519-530
    • Ogasa, M.1    Kimura, T.2    Nakamura, M.3    Guarino, J.4
  • 33
    • 0000503515 scopus 로고
    • The brief psychiatric rating-scale
    • Overall, J.E., Gorham, D.R., The brief psychiatric rating-scale. Psychol. Rep. 10 (1962), 799–812.
    • (1962) Psychol. Rep. , vol.10 , pp. 799-812
    • Overall, J.E.1    Gorham, D.R.2
  • 35
    • 84998065445 scopus 로고    scopus 로고
    • A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia
    • Potkin, S.G., Kimura, T.,J.G., A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther. Adv. Psychopharmacol. 5 (2015), 322–331.
    • (2015) Ther. Adv. Psychopharmacol. , vol.5 , pp. 322-331
    • Potkin, S.G.1    Kimura, T.J.G.2
  • 36
    • 33746341926 scopus 로고
    • The file drawer problem and tolerance for null results
    • Rosenthal, R., The file drawer problem and tolerance for null results. Psychol. Bull. 86 (1979), 638–641.
    • (1979) Psychol. Bull. , vol.86 , pp. 638-641
    • Rosenthal, R.1
  • 37
    • 22144432283 scopus 로고    scopus 로고
    • A systematic review of the prevalence of schizophrenia
    • Saha, S., Chant, D., Welham, J., McGrath, J., A systematic review of the prevalence of schizophrenia. PLoS Med., 2, 2005, e141.
    • (2005) PLoS Med. , vol.2 , pp. e141
    • Saha, S.1    Chant, D.2    Welham, J.3    McGrath, J.4
  • 38
    • 84958753867 scopus 로고    scopus 로고
    • Serotonin transporter gene polymorphism in eating disorders: data from a new biobank and meta-analysis of previous studies
    • Solmi, M., Gallicchio, D., Collantoni, E., Correll, C.U., Clementi, M., Pinato, C., et al. Serotonin transporter gene polymorphism in eating disorders: data from a new biobank and meta-analysis of previous studies. World J. Biol. Psychiatr. 17 (2016), 244–257.
    • (2016) World J. Biol. Psychiatr. , vol.17 , pp. 244-257
    • Solmi, M.1    Gallicchio, D.2    Collantoni, E.3    Correll, C.U.4    Clementi, M.5    Pinato, C.6
  • 39
    • 84946741626 scopus 로고    scopus 로고
    • The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis
    • Thomas, J.E., Caballero, J., Harrington, C.A., The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr. Neuropharmacol. 13 (2015), 681–691.
    • (2015) Curr. Neuropharmacol. , vol.13 , pp. 681-691
    • Thomas, J.E.1    Caballero, J.2    Harrington, C.A.3
  • 40
    • 85018526695 scopus 로고    scopus 로고
    • Schizophrenia
    • Van, O.J., Kapur, S., Schizophrenia. Lancet 374 (2009), 41–42.
    • (2009) Lancet , vol.374 , pp. 41-42
    • Van, O.J.1    Kapur, S.2
  • 41
    • 84942512953 scopus 로고    scopus 로고
    • Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
    • Vancampfort, D., Stubbs, B., Mitchell, A.J., De Hert, M., Wampers, M., Ward, P.B., et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatr. 14 (2015), 339–347.
    • (2015) World Psychiatr. , vol.14 , pp. 339-347
    • Vancampfort, D.1    Stubbs, B.2    Mitchell, A.J.3    De Hert, M.4    Wampers, M.5    Ward, P.B.6
  • 42
    • 84888134111 scopus 로고    scopus 로고
    • Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics
    • Wang, S.M., Han, C., Lee, S.J., Patkar, A.A., Masand, P.S., Pae, C.U., Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin. Neuropharmacol. 36 (2013), 223–238.
    • (2013) Clin. Neuropharmacol. , vol.36 , pp. 223-238
    • Wang, S.M.1    Han, C.2    Lee, S.J.3    Patkar, A.A.4    Masand, P.S.5    Pae, C.U.6
  • 43
    • 85034670008 scopus 로고    scopus 로고
    • The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis
    • Zhang, Y., Liu, Y., Su, Y., You, Y., Ma, Y., Yang, G., et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatr., 17, 2017, 373.
    • (2017) BMC Psychiatr. , vol.17 , pp. 373
    • Zhang, Y.1    Liu, Y.2    Su, Y.3    You, Y.4    Ma, Y.5    Yang, G.6
  • 44
    • 85021053158 scopus 로고    scopus 로고
    • Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials
    • Zheng, W., Li, X.H., Yang, X.H., Cai, D.B., Ungvari, G.S., Ng, C.H., et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol. Med. 48 (2018), 72–81.
    • (2018) Psychol. Med. , vol.48 , pp. 72-81
    • Zheng, W.1    Li, X.H.2    Yang, X.H.3    Cai, D.B.4    Ungvari, G.S.5    Ng, C.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.